Radiation therapy of pancreatic cancers.

{"article_title":"Radiation therapy of pancreatic cancers.","author":"Huguet F, Rivin Del Campo E, Orthuon A, Mornex F, Bessi\u00e8res I, Guimas V, Vendrely V","journal_title":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","issn":"1769-6658","isbn":"","publication_date":"2022-02-01","volume":"26","issue":"1-Feb","first_page":"259","page_count":"","accession_number":"34953706","doi":"10.1016\/j.canrad.2021.08.010","publisher":"Elsevier","doctype":"Journal Article","subjects":"France; Pancreatic Neoplasms radiotherapy; Antineoplastic Combined Chemotherapy Protocols therapeutic use; Chemoradiotherapy; Chemotherapy, Adjuvant; Fluorouracil therapeutic use; France; Humans; Induction Chemotherapy methods; Irinotecan therapeutic use; Neoadjuvant Therapy; Organ Motion; Organs at Risk radiation effects; Oxaliplatin therapeutic use; Patient Positioning; Radiation Dosage; Radiation Oncology; Radiotherapy, Intensity-Modulated; Respiration","interest_area":["Gastroenterology"," Oncology"],"abstract":"We present the update of the recommendations of the French society of oncological radiotherapy on radiotherapy of pancreatic tumors. Currently, the use of radiation therapy for patients with pancreatic cancer is subject to discussion. In the adjuvant setting, the standard treatment is six months of chemotherapy with 5-fluorouracile, irinotecan and oxaliplatin. Chemoradiation may improve the survival of patients with incompletely resected tumours (R1). This remains to be confirmed by a prospective trial. Neoadjuvant chemoradiation is a promising treatment especially for patients with borderline resectable tumours. For patients with locally advanced tumours, there is no standard. An induction chemotherapy followed by chemoradiation for non progressive patients reduces the rate of local relapse. Whereas in the first trials of chemoradiation large fields were used, the treated volumes have been reduced to improve tolerance. Tumour movements induced by breathing should be taken in account. Intensity modulated radiation therapy allows a reduction of doses to the organs at risk. Whereas widely used, this technique has poor evidence-based recommendation. Stereotactic body radiation therapy is also being studied, as a neoadjuvant or exclusive treatment. Copyright \u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34953706","isPdfLink":false,"isSAML":false,"an":"34953706","number_other":"","type_pub":"","issn_electronic":"1769-6658","languages":"English","language":"eng","date_entry":"Date Created: 20211226 Date Completed: 20220217 Latest Revision: 20220217","date_update":"20240104","titleSource":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2022 Feb-Apr; Vol. 26 (1-2), pp. 259-265. Date of Electronic Publication: 2021 Dec 23.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2022-02-01","description":"We present the update of the recommendations of the French society of oncological radiotherapy on radiotherapy of pancreatic tumors. Currently, the use of radiation therapy for patients with pancreatic cancer is subject to discussion. In the adjuvant setting, the standard treatment is six months of chemotherapy with 5-fluorouracile, irinotecan and oxaliplatin. Chemoradiation may improve the survival of patients with incompletely resected tumours (R1). This remains to be confirmed by a prospective trial. Neoadjuvant chemoradiation is a promising treatment especially for patients with borderline resectable tumours. For patients with locally advanced tumours, there is no standard. An induction chemotherapy followed by chemoradiation for non progressive patients reduces the rate of local relapse. Whereas in the first trials of chemoradiation large fields were used, the treated volumes have been reduced to improve tolerance. Tumour movements induced by breathing should be taken in account. Intensity modulated radiation therapy allows a reduction of doses to the organs at risk. Whereas widely used, this technique has poor evidence-based recommendation. Stereotactic body radiation therapy is also being studied, as a neoadjuvant or exclusive treatment.<br \/> (Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=34953706&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Huguet F, Rivin Del Campo E, Orthuon A, Mornex F, Bessi\u00e8res I, Guimas V, Vendrely V"}